retatrutide research What is Peptide Retatrutide Research: Dosing, Benefits &

PMID: 16278749

The future may involve: Sequencing and Combination: Using agents with complementary mechanisms (e.g., an incretin for weight loss combined with a myostatin inhibitor for lean mass preservation)

Associate Professor Piya is an Academic Endocrinologist at the School of Medicine, Western Sydney University as well as Head of Department for the Macarthur Diabetes Endocrinology and Metabolism Service at Campbelltown and Camden Hospitals, South Western Sydney Local Health District, NSW

In Eli Lilly's Phase 2 clinical trial (published in the New England Journal of Medicine, 2023), 338 adults with obesity or overweight (without diabetes) were treated with retatrutide for 48 weeks